Board of Directors
Mr. Hale was appointed Executive Chairman of Biocept in March 2011. He is the Chairman & CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. He was previously President and CEO of CancerVax Corporation from October 2000 through its merger in May 2006 with Micromet, Inc., a biotechnology company focused on the development of novel biological products for the treatment of cancer, when he became Chairman of the combined companies.
He is a co-founder and serves as Chairman of Somaxon Pharmaceuticals and as a director of Santarus, Inc., which are public companies, and as Chairman of SkinMedica, Inc. and as a director of Conatus Pharmaceuticals, Inc. and other private companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences technology companies. In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, he served as COO, President and then Chief Executive Officer, when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995, when Viagene was acquired by Chiron, Inc. He was President and CEO of Women First HealthCare, Inc. from late 1997 to June 2000, prior to joining CancerVax in October 2000. Prior to joining Hybritech, Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.
Mr. Nall is a healthcare executive with over 25 years of experience. He has been our President and CEO since 2013. Prior to joining Biocept, Michael served as General Manager for Clarient, a GE Healthcare Company, responsible for all commercial operations including Sales, Marketing, Client Services and Reimbursement.
Michael joined Clarient in 2002 when it was a small publicly traded company and served in several leadership roles including Director, VP of Sales, VP of Sales and Reimbursement and finally GM. During the time Michael was with Clarient, the company grew to over $110 million in revenue and was acquired by GE Healthcare. Prior to joining Clarient, Michael was with Impath, an innovative cancer diagnostic company.
Michael moved to Diagnostics after an 11 year career in the medical device and equipment industry, representing products from manufacturers like Luxtec, Pall Biomedical, Horizon Medical, Davis and Geck and others.
Michael is a native of Kansas City, MO and has a BS in Business Administration from University of Central Missouri.
Ms. Wilson has been a principal of Wilson Boyles and Company, a business management and strategic planning consulting firm, since 2003. She served on the board of directors of Farmers Insurance Group of Companies from 1993 through 2001 and the board of directors of The Home Depot, Inc. from 1992 through 2001. Ms. Wilson was also a senior officer of Home Depot from 1998 through 2002. From 1992 until 1998, Ms. Wilson served in several senior management roles at Bank of America Corporation including Chairman of Security Pacific Financial Services and Executive Vice President and Chief Credit Officer for Bank of America’s National Consumer Banking Group. She earned her Masters Degrees in International Relations and Business Administration from the University of Southern California and an Undergraduate Degree from Duke University. She became a certified public accountant in 1961.
Dr. Chandler has been the Executive Vice President/Chief Operating Officer of the Salk Institute for Biological Studies since 2007. She oversees the fiscal and administrative functions of the Institute, providing support to approximately 870 research staff and 230 administrative personnel, and oversees all fund-raising activities.
She previously served as Senior Vice Chancellor for Academic Affairs at the University of California, San Diego, where she was the chief academic officer responsible for the policies and decisions relating to all academic programs and faculty appointments and performance. She served as Acting Chancellor from 2003-04 and holds an appointment as Professor of Political Science in the Graduate School of International Relations and Pacific Studies at UCSD.
Dr. Chandler is a Fellow of the Royal Society of Canada, the highest academic honor bestowed in that country. She received her Ph.D. from The University of North Carolina at Chapel Hill.
Mr. Gerhardt has been a practicing Certified Public Accountant since 1986. He is also a tax and business advisor providing tax compliance for small businesses and upper income individuals. He earned his Bachelor of Arts Degree from the University of Southern California in 1973 and is a member of the American Institute of Certified Public Accountants.
Bruce Huebner brings to Biocept extensive executive management experience in multiple clinical diagnostic companies, including Osmetech Molecular Diagnostics, Nanogen and Gen-Probe. While serving as president of Osmetech, he successfully established the company as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products and introducing them to the marketplace.
Mr. Huebner was previously president and chief operating officer of Nanogen, a publicly held nanotechnology and microarray company. Prior to Nanogen, he was executive vice president and chief operating officer of Gen-Probe, a global leader in the development of nucleic acid tests, including diagnostic tests for infectious disease that affect women’s health. In less than 10 years, he grew Gen-Probe’s annual revenues from $42 million to a run-rate of more than $150 million. Mr. Huebner is currently a managing director of LynxCom Partners, a healthcare consulting firm with a focus on cancer diagnostics and personalized medicine.
Mr. Neff is a Healthcare investor and the CEO for SMAC, a company founded in 1990, which is a world leader and manufacturer in Moving Coil Technology. Mr. Neff earned his Bachelor of Arts and Bachelors of Science degrees from the University of Michigan.
Since 1990, Dr. Royston is a founding Managing Partner of Forward Ventures in San Diego, from 1990-2000, he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990, he was on the oncology faculty of UC, San Diego. In addition to Hybritech, he was a co-founder of IDEC Corporation in 1986, which merged with Biogen to form BiogenIdec. Dr. Royston has been instrumental in the formation, financing and development of numerous biotechnology companies, including: Applied Molecular Evolution (acquired by Eli Lilly); Corixa (acquired by GlaxoSmithKline); Dynavax; Morphotek (acquired by Eisai), Sequana Therapeutics (acquired by Celera); TargeGen (acquired by Sanofi –Aventis), and Triangle Pharmaceuticals (acquired by Gilead). Dr. Royston’s recent portfolio investments include HemaQuest, LigoCyte (Chairman), and Syndax. Dr. Royston received his B.A. (1967) and M.D. (1970) degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board.